UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Beaumont RN
(2022)
Estimating diagnostic noise in panel-based genomic analysis.
in Genetics in medicine : official journal of the American College of Medical Genetics
Beck JJ
(2021)
Genetic meta-analysis of twin birth weight shows high genetic correlation with singleton birth weight.
in Human molecular genetics
Becker J
(2021)
Resource profile and user guide of the Polygenic Index Repository.
in Nature human behaviour
Beeler J
(2022)
Genetic causes and cardiovascular consequences of clonal hematopoiesis in the UK Biobank
in Nature Cardiovascular Research
Beesley L
(2019)
The emerging landscape of health research based on biobanks linked to electronic health records: Existing resources, statistical challenges, and potential opportunities
in Statistics in Medicine
Beetz M
(2022)
Multi-Domain Variational Autoencoders for Combined Modeling of MRI-Based Biventricular Anatomy and ECG-Based Cardiac Electrophysiology.
in Frontiers in physiology
Behrendt I
(2021)
Gluten intake and metabolic health: conflicting findings from the UK Biobank.
in European journal of nutrition
Behrendt I
(2021)
Gluten Intake and All-Cause and Cause-Specific Mortality: Prospective Findings from the UK Biobank.
in The Journal of nutrition
Behrendt I
(2020)
Association of Antioxidants Use with All-Cause and Cause-Specific Mortality: A Prospective Study of the UK Biobank.
in Antioxidants (Basel, Switzerland)
Belete D
(2023)
Association Between Antiepileptic Drugs and Incident Parkinson Disease.
in JAMA neurology
Belete D
(2022)
Parkinson's disease determinants, prediction and gene-environment interac- tions: a UK Biobank study
in Journal of Neurology, Neurosurgery & Psychiatry
Bell JA
(2022)
Effects of general and central adiposity on circulating lipoprotein, lipid, and metabolite levels in UK Biobank: A multivariable Mendelian randomization study.
in The Lancet regional health. Europe
Bell S
(2021)
A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis.
in Communications biology
Bell S
(2022)
Genome-wide association study of the human brain functional connectome reveals strong vascular component underlying global network efficiency.
in Scientific reports
Bellot P
(2018)
Can Deep Learning Improve Genomic Prediction of Complex Human Traits?
in Genetics
Bellou E
(2020)
Age-dependent effect of APOE and polygenic component on Alzheimer's disease.
in Neurobiology of aging
Bellows B
(2022)
Estimated Yield of Screening for Heterozygous Familial Hypercholesterolemia With and Without Genetic Testing in US Adults
in Journal of the American Heart Association
Belonogova N
(2023)
Noncoding rare variants in PANX3 are associated with chronic back pain
in Pain
Belonogova N
(2022)
sumSTAAR: A flexible framework for gene-based association studies using GWAS summary statistics
in PLOS Computational Biology
Benjamins JW
(2022)
Genomic insights in ascending aortic size and distensibility.
in EBioMedicine
Benn M
(2023)
Obesity increases heart failure incidence and mortality: observational and Mendelian randomization studies totalling over 1 million individuals.
in Cardiovascular research
Bennett C
(2022)
Iron homeostasis governs erythroid phenotype in Polycythemia Vera
Bennett E
(2018)
Sex differences in macronutrient intake and adherence to dietary recommendations: findings from the UK Biobank.
in BMJ open
Bernabeu E
(2021)
Sex differences in genetic architecture in the UK Biobank.
in Nature genetics
Berrandou T
(2023)
LDAK-GBAT: Fast and powerful gene-based association testing using summary statistics
in The American Journal of Human Genetics
Berry ASF
(2023)
Association of Supernumerary Sex Chromosome Aneuploidies With Venous Thromboembolism.
in JAMA
Bethlehem RAI
(2022)
Brain charts for the human lifespan.
in Nature
Beyer SE
(2018)
Prospective association between handgrip strength and cardiac structure and function in UK adults.
in PloS one
Bhatt IS
(2022)
A genome-wide association study of tinnitus reveals shared genetic links to neuropsychiatric disorders.
in Scientific reports
Bhattacharya R
(2021)
Association of Diet Quality With Prevalence of Clonal Hematopoiesis and Adverse Cardiovascular Events.
in JAMA cardiology
Bhui K
(2021)
Is psychosis a syndemic manifestation of historical and contemporary adversity? Findings from UK Biobank.
in The British journal of psychiatry : the journal of mental science
Bi W
(2020)
A Fast and Accurate Method for Genome-Wide Time-to-Event Data Analysis and Its Application to UK Biobank.
in American journal of human genetics
Bi W
(2019)
A Fast and Accurate Method for Genome-wide Scale Phenome-wide G × E Analysis and Its Application to UK Biobank.
in American journal of human genetics
Bi W
(2021)
Efficient mixed model approach for large-scale genome-wide association studies of ordinal categorical phenotypes.
in American journal of human genetics
Bian B
(2022)
The role of critical immune genes in brain disorders: insights from neuroimaging immunogenetics.
in Brain communications
Bianco C
(2021)
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores.
in Journal of hepatology
Bianco C
(2021)
Genetic insight into COVID-19-related liver injury.
in Liver international : official journal of the International Association for the Study of the Liver
Bick AG
(2020)
Genetic Interleukin 6 Signaling Deficiency Attenuates Cardiovascular Risk in Clonal Hematopoiesis.
in Circulation
Biddinger KJ
(2022)
Association of Habitual Alcohol Intake With Risk of Cardiovascular Disease.
in JAMA network open
Biddinger KJ
(2022)
Rare and Common Genetic Variation Underlying the Risk of Hypertrophic Cardiomyopathy in a National Biobank.
in JAMA cardiology
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |